CFS & Long COVID

What they are

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and Long COVID are chronic, multisystem illnesses that typically begin after an infection and produce profound, persistent disability. They are treated together here because the scientific consensus has increasingly converged on the view that they are closely related — overlapping members of a broader family sometimes called post-acute infection syndromes, in which an initial infection triggers downstream processes that lead to chronic, multisystem dysfunction. ME/CFS classically follows a range of viral infections; Long COVID follows SARS-CoV-2 specifically. Their features overlap substantially, though they are not identical.

These conditions occupy a fraught place in medicine. For decades, ME/CFS patients were disbelieved, told their illness was purely psychological, and sometimes harmed by the treatments that followed from that belief. Long COVID, arriving at scale during the pandemic, forced a broader reckoning. A starting principle for any honest account is that these are real, biologically based illnesses that are also, at present, incompletely understood and lacking proven cures — and that holding both halves of that statement at once, without retreating into either dismissal or false certainty, is what the evidence demands.

The core features

Despite varied individual presentations, several hallmark symptoms recur across both conditions: disabling fatigue not relieved by rest; cognitive dysfunction ("brain fog"); unrefreshing sleep; orthostatic intolerance and other signs of autonomic dysfunction; and — most distinctively — post-exertional malaise (PEM).

Definitions and subtypes

For ME/CFS, the influential 2015 Institute of Medicine criteria require a substantial reduction in functioning for at least six months, accompanied by PEM and unrefreshing sleep, plus either cognitive impairment or orthostatic intolerance — and the report proposed (though it did not stick) the name "systemic exertion intolerance disease" precisely to foreground PEM. Severity ranges enormously, from people who can work part-time with accommodations to those who are housebound or bedbound.

For Long COVID (also called post-acute sequelae of SARS-CoV-2 infection, or PASC), definitions have been actively developed, including a major symptom-based research definition from the NIH-funded RECOVER initiative, with symptoms persisting beyond roughly three months after infection. Long COVID is heterogeneous — it includes a fatigue/PEM-predominant phenotype that closely resembles ME/CFS, but also distinct presentations dominated by breathlessness, cardiovascular, or other organ-specific symptoms — and research increasingly tries to identify symptom-based subgroups that may respond differently to treatment.

What causes them

The mechanisms are multifactorial and still being worked out, but several converging candidates have substantial support across both conditions: viral persistence (lingering viral material or reservoirs driving ongoing immune activation), immune dysregulation and autoimmunity, endothelial and microvascular dysfunction (problems with the lining of blood vessels and with blood flow), autonomic nervous system dysfunction, mitochondrial and metabolic disturbances in cellular energy, and neuroinflammation. These map directly onto themes that run throughout this library — inflammation and sickness behavior, mitochondrial dysfunction and bioenergetics, autonomic and HPA dysregulation — and they help explain why fatigue, brain fog, and unrefreshing sleep co-occur as a cluster. No single mechanism fully accounts for either illness, and it is likely that several operate together and differ between patients.

How they are diagnosed

Both are clinical diagnoses of exclusion: there is no diagnostic blood test, scan, or biomarker, so diagnosis rests on the characteristic symptom pattern (above all PEM) together with the exclusion of other conditions that can mimic it. For ME/CFS, this means ruling out other causes of chronic fatigue — including thyroid disease, anemia, sleep disorders, and, notably, Long COVID and post-treatment Lyme disease, which overlap closely. The absence of a confirmatory test is a source of real difficulty and of the historical skepticism these patients have faced, but it does not make the illnesses any less real — it places them, for now, alongside many conditions diagnosed by pattern rather than by laboratory proof.

A crucial differential is depression. Although fatigue and cognitive symptoms overlap, the conditions differ: PEM is not a feature of depression, and many people with ME/CFS or Long COVID retain interest and motivation but are physically unable to act on them — closer to being trapped behind a wall of exhaustion than to the loss of anhedonia. Conflating the two is a frequent and consequential error.

Course and prognosis

The course is variable and often prolonged. Some people with Long COVID recover over months; others remain ill for years, and a subset develop a persistent illness meeting ME/CFS criteria. ME/CFS itself tends to be chronic, with fluctuations, periods of partial improvement, and — for many — substantial long-term disability. Predicting an individual's trajectory is currently not possible, which is itself a source of distress and uncertainty that good care must acknowledge.

Treatment

There are, at present, no FDA-approved treatments and no proven cures for either ME/CFS or Long COVID. Management is therefore organized around symptom relief, protecting function, and — above all — avoiding harm. This honesty is not nihilism; it is the foundation of responsible care, and it stands in contrast to the many unproven and sometimes exploitative "cures" marketed to desperate patients.

The cornerstone of management is pacing — staying within one's "energy envelope" to avoid triggering PEM. This represents a hard-won correction to earlier practice. For years, prescriptive graded exercise therapy (steadily increasing activity) was recommended for ME/CFS, but in conditions defined by PEM, pushing through exertion can cause lasting deterioration; current guidance (including the UK's NICE guideline, substantially revised in 2021) no longer recommends graded exercise as a treatment and emphasizes individualized pacing and energy management instead. This distinction is the most important practical point in the document: activity advice that is reasonable for depression-related fatigue can be actively harmful here.

Beyond pacing, care is symptomatic and individualized: treating orthostatic intolerance, sleep, pain, and any identifiable contributors; addressing co-occurring depression or anxiety where present (as understandable consequences of a disabling chronic illness, not as the cause); and multidisciplinary rehabilitation oriented around the person's limits rather than against them. Cognitive behavioral therapy has a contested history here — when offered as a cure premised on the illness being psychological, it was rightly rejected by patients; when offered as supportive coping with a real physical illness, like CBT for any serious medical condition, it can have a limited adjunctive role, and the distinction matters enormously to a community that has been ill-served. A large patient-reported-outcomes literature is now being used to identify which symptomatic strategies patients find helpful and to nominate candidates for proper trials.

Research is active. The NIH RECOVER initiative is a large, well-funded effort — though one criticized for the slow pace of its clinical trials — and a growing recognition of the overlap between Long COVID and ME/CFS is, at last, beginning to unify research that was historically siloed. For now, the honest message to patients is that effective specific treatment does not yet exist, that careful symptom management and pacing are the mainstays, and that the science is moving, if not as fast as the need.

Controversies and honest caveats

These conditions are surrounded by genuine, high-stakes debate. The history of psychologizing ME/CFS — treating a physical illness as a primarily mental one — caused real harm and justified deep patient mistrust, and any framing that minimizes the biological reality of these conditions repeats that error. The graded exercise controversy is the clinical expression of this and is now largely resolved in favor of pacing. The absence of biomarkers keeps diagnosis difficult and leaves room for both under-recognition and, occasionally, misattribution. And the relationship between the two conditions — how much Long COVID is "new" versus a large, infection-specific instance of a long-known post-viral syndrome — is itself an active and clarifying scientific question.

Bottom line

ME/CFS and Long COVID are real, disabling, biologically based illnesses that typically follow infection and share a core of symptoms — disabling fatigue, cognitive dysfunction, unrefreshing sleep, autonomic dysfunction, and, definingly, post-exertional malaise. Their mechanisms are multifactorial and still being mapped (viral persistence, immune dysregulation, endothelial and autonomic dysfunction, mitochondrial and neuroinflammatory processes), they are diagnosed clinically by pattern and exclusion because no biomarker exists, and they currently have no proven cure. The most important practical truths are that they must be distinguished from depression, that PEM makes "push through it" advice potentially harmful, and that pacing and careful symptomatic management — offered with belief rather than skepticism — are the foundation of care while the science, finally gaining momentum, works toward treatments these patients have waited far too long for.

Selected references

1. Institute of Medicine. Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness. National Academies Press; 2015.
2. Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023.
3. Thaweethai T, et al. Development of a definition of postacute sequelae of SARS-CoV-2 infection (RECOVER). JAMA. 2023.
4. Komaroff AL, Lipkin WI. ME/CFS and Long COVID share similar symptoms and biological abnormalities. Front Med. 2023.
5. Komaroff AL. Growing recognition of post-acute infection syndromes. Proc Natl Acad Sci USA. 2025.
6. National Institute for Health and Care Excellence (NICE). Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and management (NG206). 2021.
7. Eckey M, et al. Patient-reported treatment outcomes in ME/CFS and long COVID. Proc Natl Acad Sci USA. 2025.
8. Nath A. Long-haul COVID. Neurology. 2020.
9. Systrom DM, et al. Exercise pathophysiology and post-exertional malaise (invasive cardiopulmonary exercise testing). Front Physiol / related work.
10. Carruthers BM, et al. Myalgic encephalomyelitis: international consensus criteria. J Intern Med. 2011.
11. Proal AD, VanElzakker MB. Long COVID or post-acute sequelae of COVID-19 (PASC): an overview of biological factors that may contribute to persistent symptoms. Front Microbiol. 2021.
12. Al-Aly Z, et al. Long COVID: long-term health outcomes and implications. Nat Med / Nat Rev Nephrol (Al-Aly long COVID cohort work). 2024.
13. Bonilla H, et al. Long COVID clinical phenotypes and management. Front Med. 2023.
14. Walitt B, et al. Deep phenotyping of post-infectious ME/CFS (NIH intramural study). Nat Commun. 2024.
15. Vernon SD, et al. Post-exertional malaise in ME/CFS and Long COVID. Work / J Transl Med. (PEM characterization.)
16. CDC. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) — information for healthcare providers. 2024.